Haifeng Liu , Ying Zhang , Zeyong Zhong , Yanchun Gong , Pingting Yu , Yuhan Yang , Yichi Zhang , Tieli Zhou , Lijiang Chen
{"title":"免疫调节剂 AS101 可在体外和体内恢复临床耐大肠杆菌和肺炎克雷伯菌对大肠菌素的敏感性。","authors":"Haifeng Liu , Ying Zhang , Zeyong Zhong , Yanchun Gong , Pingting Yu , Yuhan Yang , Yichi Zhang , Tieli Zhou , Lijiang Chen","doi":"10.1016/j.ijantimicag.2024.107285","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Colistin (COL) was once considered to be the last line of defence against multidrug-resistant bacteria belonging to the family <em>Enterobacteriaceae</em>. Due to the misuse of COL, COL-resistant (COL-R) <em>Enterobacteriaceae</em> have emerged. To address this clinical issue and combat COL resistance, novel approaches are urgently needed.</p></div><div><h3>Methods</h3><p>In this study, the in vitro and in vivo antimicrobial and antibiofilm effects of the immunomodulator AS101 were investigated in combination with COL against COL-R <em>Escherichia coli</em> (<em>E. coli</em>) and <em>Klebsiella pneumoniae</em> (<em>K. pneumoniae</em>).</p></div><div><h3>Results</h3><p>Checkerboard assay, time-kill assay, and scanning electron microscopy confirmed the in vitro antimicrobial phenotype, whereas, crystal violet staining and multidimensional confocal laser scanning microscopy with live/dead staining confirmed the antibiofilm capability of the combination therapy. Moreover, the <em>Galleria mellonella</em> infection model and the mouse infection model indicated the high in vivo efficacy of the combination therapy. Additionally, cytotoxicity experiments performed using human kidney-derived HK-2 cells and haemolysis assays performed using human erythrocytes collectively demonstrated safety at effective combination concentrations. Furthermore, quantification of the expression of inflammatory cytokines via enzyme-linked immunosorbent assay confirmed the anti-inflammatory advantage of combination therapy. At the mechanistic level, changes in outer and inner membrane permeability and accumulation of ROS levels, which might be potential mechanisms for synergistic antimicrobial effects.</p></div><div><h3>Conclusions</h3><p>This study found that AS101 can restore COL susceptibility in clinical COL-R <em>E. coli</em> and <em>K. pneumoniae</em> and also has synergistic antibiofilm and anti-inflammatory capabilities. This study provided a novel strategy to combat clinical infections caused by COL-R <em>E. coli</em> and <em>K. pneumoniae</em>.</p></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"64 4","pages":"Article 107285"},"PeriodicalIF":4.9000,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunomodulator AS101 restores colistin susceptibility of clinical colistin-resistant Escherichia coli and Klebsiella pneumoniae in vitro and in vivo\",\"authors\":\"Haifeng Liu , Ying Zhang , Zeyong Zhong , Yanchun Gong , Pingting Yu , Yuhan Yang , Yichi Zhang , Tieli Zhou , Lijiang Chen\",\"doi\":\"10.1016/j.ijantimicag.2024.107285\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Colistin (COL) was once considered to be the last line of defence against multidrug-resistant bacteria belonging to the family <em>Enterobacteriaceae</em>. Due to the misuse of COL, COL-resistant (COL-R) <em>Enterobacteriaceae</em> have emerged. To address this clinical issue and combat COL resistance, novel approaches are urgently needed.</p></div><div><h3>Methods</h3><p>In this study, the in vitro and in vivo antimicrobial and antibiofilm effects of the immunomodulator AS101 were investigated in combination with COL against COL-R <em>Escherichia coli</em> (<em>E. coli</em>) and <em>Klebsiella pneumoniae</em> (<em>K. pneumoniae</em>).</p></div><div><h3>Results</h3><p>Checkerboard assay, time-kill assay, and scanning electron microscopy confirmed the in vitro antimicrobial phenotype, whereas, crystal violet staining and multidimensional confocal laser scanning microscopy with live/dead staining confirmed the antibiofilm capability of the combination therapy. Moreover, the <em>Galleria mellonella</em> infection model and the mouse infection model indicated the high in vivo efficacy of the combination therapy. Additionally, cytotoxicity experiments performed using human kidney-derived HK-2 cells and haemolysis assays performed using human erythrocytes collectively demonstrated safety at effective combination concentrations. Furthermore, quantification of the expression of inflammatory cytokines via enzyme-linked immunosorbent assay confirmed the anti-inflammatory advantage of combination therapy. At the mechanistic level, changes in outer and inner membrane permeability and accumulation of ROS levels, which might be potential mechanisms for synergistic antimicrobial effects.</p></div><div><h3>Conclusions</h3><p>This study found that AS101 can restore COL susceptibility in clinical COL-R <em>E. coli</em> and <em>K. pneumoniae</em> and also has synergistic antibiofilm and anti-inflammatory capabilities. This study provided a novel strategy to combat clinical infections caused by COL-R <em>E. coli</em> and <em>K. pneumoniae</em>.</p></div>\",\"PeriodicalId\":13818,\"journal\":{\"name\":\"International Journal of Antimicrobial Agents\",\"volume\":\"64 4\",\"pages\":\"Article 107285\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2024-08-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Antimicrobial Agents\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0924857924002036\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Antimicrobial Agents","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924857924002036","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
可乐定(COL)曾一度被认为是抵抗肠杆菌科多重耐药细菌的最后一道防线。由于滥用 COL,出现了对 COL 耐药(COL-R)的肠杆菌科细菌。为解决这一临床问题并对抗 COL 耐药性,迫切需要新的方法。本研究研究了免疫调节剂 AS101 与 COL 联用对 COL-R 大肠埃希菌(大肠杆菌)和肺炎克雷伯菌(肺炎克雷伯菌)的体外和体内抗菌和抗生物膜作用。棋盘试验、时间杀伤试验和扫描电子显微镜证实了体外抗菌表型,而水晶紫染色和多维共焦激光扫描显微镜活/死染色证实了联合疗法的抗生物膜能力。此外,黑线梭菌感染模型和小鼠感染模型也表明,该组合疗法在体内具有很高的疗效。此外,利用人体肾脏衍生的 HK-2 细胞进行的细胞毒性实验和利用人体红细胞进行的溶血实验共同证明了有效组合浓度下的安全性。此外,通过酶联免疫吸附试验(ELISA)对炎症细胞因子的表达进行量化,证实了联合疗法的抗炎优势。在机理层面,外膜和内膜通透性的变化以及 ROS 水平的积累,可能是协同抗菌作用的潜在机制。总之,本研究发现 AS101 可恢复临床 COL-R 大肠杆菌和肺炎双球菌对 COL 的敏感性,同时还具有协同抗生物膜和抗炎能力。这项研究为抗击由 COL-R 大肠杆菌和肺炎双球菌引起的临床感染提供了一种新策略。
Immunomodulator AS101 restores colistin susceptibility of clinical colistin-resistant Escherichia coli and Klebsiella pneumoniae in vitro and in vivo
Objectives
Colistin (COL) was once considered to be the last line of defence against multidrug-resistant bacteria belonging to the family Enterobacteriaceae. Due to the misuse of COL, COL-resistant (COL-R) Enterobacteriaceae have emerged. To address this clinical issue and combat COL resistance, novel approaches are urgently needed.
Methods
In this study, the in vitro and in vivo antimicrobial and antibiofilm effects of the immunomodulator AS101 were investigated in combination with COL against COL-R Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae).
Results
Checkerboard assay, time-kill assay, and scanning electron microscopy confirmed the in vitro antimicrobial phenotype, whereas, crystal violet staining and multidimensional confocal laser scanning microscopy with live/dead staining confirmed the antibiofilm capability of the combination therapy. Moreover, the Galleria mellonella infection model and the mouse infection model indicated the high in vivo efficacy of the combination therapy. Additionally, cytotoxicity experiments performed using human kidney-derived HK-2 cells and haemolysis assays performed using human erythrocytes collectively demonstrated safety at effective combination concentrations. Furthermore, quantification of the expression of inflammatory cytokines via enzyme-linked immunosorbent assay confirmed the anti-inflammatory advantage of combination therapy. At the mechanistic level, changes in outer and inner membrane permeability and accumulation of ROS levels, which might be potential mechanisms for synergistic antimicrobial effects.
Conclusions
This study found that AS101 can restore COL susceptibility in clinical COL-R E. coli and K. pneumoniae and also has synergistic antibiofilm and anti-inflammatory capabilities. This study provided a novel strategy to combat clinical infections caused by COL-R E. coli and K. pneumoniae.
期刊介绍:
The International Journal of Antimicrobial Agents is a peer-reviewed publication offering comprehensive and current reference information on the physical, pharmacological, in vitro, and clinical properties of individual antimicrobial agents, covering antiviral, antiparasitic, antibacterial, and antifungal agents. The journal not only communicates new trends and developments through authoritative review articles but also addresses the critical issue of antimicrobial resistance, both in hospital and community settings. Published content includes solicited reviews by leading experts and high-quality original research papers in the specified fields.